A Phase I Study of NeuroVax(TM), a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis
Status: Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs IR 902 (Primary) ; Incomplete Freund's adjuvant
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Immune Response BioPharma
- 31 Aug 2018 Biomarkers information updated
- 22 Feb 2016 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019, according to ClinicalTrials.gov record.
- 22 Feb 2016 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019, according to ClinicalTrials.gov record.